NeuroSense Therapeutics Ltd. filed a Form 6-K on October 26, 2026, disclosing that it has signed a strategic collaboration agreement with an advisor to advance a revenue-generating supply of PrimeC, its lead ALS therapeutic candidate, to eligible patients through a licensed clinical treatment center in the United States.

Key Highlights

  • Agreement signed: NeuroSense entered a strategic collaboration agreement with an advisor focused on commercializing PrimeC supply to ALS patients through a licensed U.S. clinical treatment center.
  • Revenue target: The company is targeting first revenues from PrimeC supply in the first half of 2027, subject to completion of applicable legal, regulatory, and operational requirements.
  • Advisor compensation: The company agreed to pay the advisor in equity and on a success-based percentage of net revenues generated from qualifying sales resulting from the advisor's activities.
  • Pathway described: The commercialization would take place through "a potential pathway that may permit access to and commercialization of certain investigational therapies prior to traditional marketing approval."
  • Demand cited: The agreement follows, according to the filing, "sustained demand from ALS patients and physicians seeking access to PrimeC outside of clinical trials."
  • Ongoing programs: The filing notes the effort is intended to run alongside the company's continuing clinical programs in ALS and Alzheimer's disease.

NeuroSense Moves to Establish Initial PrimeC Revenue Stream

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN), an Israeli biopharmaceutical company, disclosed via a Form 6-K for the month of October 2026 that it has signed a strategic collaboration agreement aimed at supplying PrimeC to ALS patients in the United States. According to the filing, this supply would occur through a licensed clinical treatment center and would use a pathway that may allow access to investigational therapies before traditional marketing approval is obtained.

The company disclosed that it is targeting first revenues from PrimeC supply in the first half of 2027, though the filing notes this is subject to "completion of applicable legal, regulatory and operational requirements." As consideration for the advisor's services, NeuroSense agreed to pay in equity and through a success-based percentage of net revenues tied to qualifying sales resulting from the advisor's work. No fixed cash fee amount was specified in the filing.

The filing states the agreement "is intended to support the Company's efforts to establish a potential initial revenue stream from PrimeC supply and potentially marks a pivotal transition for NeuroSense toward a revenue-generating business." The company also noted in its forward-looking statements section that risks include the possibility the described pathway "may not be available or may not permit the commercialization of PrimeC on acceptable terms or at all." The forward-looking statements contained in the filing are the company's own and are subject to the cautionary language included in the report, with additional risk factors described in the Annual Report on Form 20-F filed with the SEC on March 31, 2026.

What Was Disclosed

NeuroSense Therapeutics filed a Form 6-K reporting a newly signed strategic collaboration agreement to supply PrimeC to ALS patients through a U.S. clinical treatment center, targeting first revenues in the first half of 2027 and compensating the advisor in equity and revenue-based payments.